Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca to present new lung cancer data at ESMO 2017

AstraZeneca to present new lung cancer data at ESMO 2017

31st August 2017

AstraZeneca has announced plans to share new findings on a number of lung cancer advances at this year's European Society of Medical Oncology (ESMO) Congress.

The company will attend the conference from September 8th to 12th in Madrid to give more than 40 presentations, including two pivotal clinical trial readouts selected for late-breaking abstract presentation at the ESMO Presidential Symposia on September 9th.

These will include findings from the phase III PACIFIC trial that demonstrate the statistically significant and clinically meaningful progression-free survival benefits associated with Imfinzi in patients with locally-advanced unresectable non-small cell lung cancer (NSCLC).

Additionally, the firm will share the results of the phase III FLAURA trial, which will highlight the survival benefits of Tagrisso compared to current standard-of-care therapies in treating locally-advanced or metastatic epidermal growth factor receptor mutation-positive NSCLC.

Jamie Freedman, executive vice-president and head of the oncology business unit at AstraZeneca, said: "The superiority of first-line treatment with Tagrisso in the FLAURA trial and the potentially transformative Imfinzi data from the PACIFIC trial reinforce our significant contribution to advancing medicines for patients across multiple stages of lung cancer."

With over 20 years of experience within the pharmaceutical market, we at Zenopa have the knowledge, skills and expertise to help find the right job for you. To find out more about the current pharmaceutical roles we have available, you can search for the latest job roles, register your details, or contact the team today.ADNFCR-8000103-ID-801839448-ADNFCR

We currently have 8 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.